Trial Profile
A RANDOMIZED PHASE II STUDY COMPARING IMATINIB AND THE COMBINATION OF IMATINIB AND PEGYLATED INTERFERON ALPHA-2B IN NEWLY DIAGNOSED NON-HIGH RISK CHRONIC MYELOID LEUKEMIA PATIENTS IN COMPLETE HEMATOLOGICAL REMISSION AFTER IMATINIB INDUCTION THERAPY
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2011
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Peginterferon alfa-2b (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms Nordic IR-LR
- 17 Jun 2011 Results published in Blood.
- 05 Nov 2010 New trial record.